TY - JOUR
T1 - GLP-1 Agonist Use Among Men With Localized Prostate Cancer
T2 - A Narrative Review and Rationale for Prospective Clinical Trials
AU - Fang, Andrew
AU - Frigo, Daniel E.
AU - Hahn, Andrew
AU - Razouki, Zayd
AU - Hwang, Jessica
AU - Koutroumpakis, Efstratios
AU - Lawen, Tarek
AU - Smith, Matthew
AU - Hamilton-Reeves, Jill
AU - DiGiovanni, John
AU - Higgason, Noel
AU - Garcia, Rebekka S.
AU - Chapin, Brian F.
AU - Pettaway, Curtis
AU - Chery, Lisly
AU - Troncoso, Patricia
AU - Logothetis, Christopher
AU - Daniel, Carrie R.
AU - Wei, Peng
AU - Gregg, Justin R.
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/7
Y1 - 2025/7
N2 - Glucagon-like peptide 1 (GLP-1) receptor agonists are a revolutionary treatment for obesity, and investigations into other uses of these agents are ongoing. Epidemiologic data suggest that prostate cancer risk may decrease following GLP-1 receptor agonist initiation. To better define the potential role of GLP-1 receptor agonist use among men with prostate cancer, we will define changes that occur in men with prostate cancer following lifestyle intervention; illuminate the current relationship between these interventions and prostate cancer risk; and explore the potential mechanism of action on tumor biology, providing rationale for evaluating its effects on prostate cancer in a planned clinical trial.
AB - Glucagon-like peptide 1 (GLP-1) receptor agonists are a revolutionary treatment for obesity, and investigations into other uses of these agents are ongoing. Epidemiologic data suggest that prostate cancer risk may decrease following GLP-1 receptor agonist initiation. To better define the potential role of GLP-1 receptor agonist use among men with prostate cancer, we will define changes that occur in men with prostate cancer following lifestyle intervention; illuminate the current relationship between these interventions and prostate cancer risk; and explore the potential mechanism of action on tumor biology, providing rationale for evaluating its effects on prostate cancer in a planned clinical trial.
UR - https://www.scopus.com/pages/publications/105006813734
UR - https://www.scopus.com/pages/publications/105006813734#tab=citedBy
U2 - 10.1016/j.urology.2025.04.056
DO - 10.1016/j.urology.2025.04.056
M3 - Review article
C2 - 40348027
AN - SCOPUS:105006813734
SN - 0090-4295
VL - 201
SP - 152
EP - 158
JO - Urology
JF - Urology
ER -